Efficacy and Safety of film forming spray in a patient with plaque psoriasis

Clinical Evaluation of Film forming spray (FFS)in Patients with Plaque Psoriasis A Prospective Open labelled Split Body Comparative Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076621

Enrollment

Registered

2024-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L40- Psoriasis

Interventions

Intervention1: clobetasol ointment with film forming spray: this is a split body comparative study at one side patient asked to apply clobetasol ointment with film forming spray and at other side pati

Eligibility

Inclusion criteria

Inclusion criteria: outpatients aged =18 years with mild to moderate chronic stable plaque psoriasis affecting =10% BSA Patients having at least 2 symmetrical psoriatic lesions that are similar in erythema, induration, and scaling. Target lesions (plaques) diameter =5 cm Target lesions (plaques) must have had a total modified HD PASI score of 4 or greater and are within 1 point of each other for each of the 3 parameters (erythema, induration, and scaling) Willing to comply with study procedures, treatments (topical steroid ointment application) and assessments

Exclusion criteria

Exclusion criteria: Lesion localized to scalp, face, groin area Use of biological therapies/systemic anti-psoriatic treatment (previous 12 weeks). Patients with evidence of a skin disorder other than plaque-type psoriasis, clinically infected psoriasis, and/or skin atrophy in the area of the target lesion. Hypersensitivity to alcohol-based preparation Pregnancy , Lactation Severe renal impairment or severe hepatic disorders Use of topical Anti-psoriatic in last 4 weeks.

Design outcomes

Primary

Measure	Time frame
To asses the Change from baseline in the overall severity score (OSS) of psoriatic plaques at the end of 4 weeks. Timepoint: 4 weeks	—

Secondary

Measure	Time frame
To asses the Change from baseline in the overall severity score (OSS) of psoriatic plaques at the week 1 and week 2. To assess Change from baseline in the scores for Modified HD PASI (High Discrimination Psoriasis Area and Severity Index) for target lesion at the end of 4 weeks. Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactBikash Ranjan Kar

Institute of medical science and sum Hospital

bikashkar@soa.ac.in7978286893

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026